All In Biotech

Drug Trial Radar · NCT03691909

Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis

A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

15

Actual

Start

Sep 25, 2018

Primary completion

Aug 17, 2020

Study completion Sep 28, 2020

Sponsor

Lead sponsor
Hope Biosciences LLCIndustry
Sponsor type
Industry
First posted
Oct 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hope Biosciences is conducting a research study of an investigational product called Hope Biosciences autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment for Rheumatoid Arthritis (RA). The study purpose is to evaluate the safety profile of a single IV infusion of HB-adMSCs in subjects with clinical diagnosis of RA.

Conditions

  • Rheumatoid Arthritis

Interventions

  • HB-adMSCsBiological

    Hope Biosciences autologous adipose-derived mesenchymal stem cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Number of Adverse Events and Serious Adverse EventsTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Accurate Clinical Research

    Pasadena, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.